In the latest Phase 2a trial of the pancreatic cancer treatment from Israel’s BioLineRx (see here) three-quarters of the patients at disease stage 4 were able to get their disease under control. The trial combined BL-8040, KEYTRUDA (Pembrolizumab) and chemotherapy.

https://www.jpost.com/HEALTH-SCIENCE/New-Israeli-pancreatic-cancer-treatment-could-extend-most-patients-lives-611085

https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-preliminary-phase-2a-data-triple-combination